U.S. Markets open in 3 hrs 12 mins
  • S&P Futures

    3,418.25
    -14.25 (-0.42%)
     
  • Dow Futures

    28,020.00
    -114.00 (-0.41%)
     
  • Nasdaq Futures

    11,639.50
    -51.75 (-0.44%)
     
  • Russell 2000 Futures

    1,600.40
    -2.70 (-0.17%)
     
  • Crude Oil

    40.11
    +0.08 (+0.20%)
     
  • Gold

    1,918.60
    -10.90 (-0.56%)
     
  • Silver

    24.88
    -0.36 (-1.43%)
     
  • EUR/USD

    1.1833
    -0.0034 (-0.2840%)
     
  • 10-Yr Bond

    0.8160
    0.0000 (0.00%)
     
  • Vix

    29.51
    +0.16 (+0.55%)
     
  • GBP/USD

    1.3108
    -0.0035 (-0.2674%)
     
  • USD/JPY

    104.6900
    +0.1300 (+0.1243%)
     
  • BTC-USD

    12,883.75
    +1,826.74 (+16.52%)
     
  • CMC Crypto 200

    258.37
    +13.48 (+5.51%)
     
  • FTSE 100

    5,752.55
    -23.95 (-0.41%)
     
  • Nikkei 225

    23,474.27
    -92.73 (-0.39%)
     

Alnylam to Webcast Presentations at Upcoming May Investor Conferences

·2 mins read

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences being held virtually:

  • Bank of America Securities 2020 Health Care Conference on Thursday, May 14, 2020 at 9:40 am ET

  • UBS Global Healthcare Conference on Wednesday, May 20, 2020 at 12:30 pm ET

A live audio webcast of each presentation will be available on the Investors section of the Company’s website at www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after each event.

About Alnylam Pharmaceuticals

Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam’s commercial RNAi therapeutic products are ONPATTRO® (patisiran), approved in the U.S., EU, Canada, Japan, Switzerland and Brazil, and GIVLAARI® (givosiran), approved in the U.S. and EU. Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam is executing on its "Alnylam 2020" strategy of building a multi-product, commercial-stage biopharmaceutical company with a sustainable pipeline of RNAi-based medicines to address the needs of patients who have limited or inadequate treatment options. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam or on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200511005274/en/

Contacts

Alnylam Pharmaceuticals, Inc.
Christine Regan Lindenboom
(Investors and Media)
617-682-4340

Josh Brodsky
(Investors)
617-551-8276